Navigation Links
PeriGen, Inc. Forms Strategic Alliance with Willis Healthcare to Improve Quality of Care in OB

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- PeriGen, Inc., the only OB-specific risk reduction company to provide solutions which generate immediate quantifiable clinical and financial value, today announced the formation of a strategic alliance with Willis Group Holdings (NYSE: WSH), a leading global insurance broker and one of the world's largest professional services firms specializing in risk management. According to the terms of the alliance, Willis will offer PeriGen's unique OB-specific products and services to its clients, in an effort to reduce risk and associated medical malpractice costs by improving the quality of care delivered.

"As medical malpractice insurance brokers and experts in risk management, we are very aware of the cost of errors in Obstetrics," said Mary S. Botkin, Managing Director, Willis National Health Care. "Obstetrics ranks first among all specialties for the number of claims reported and for the total amount of indemnity paid. PeriGen's solutions address the root causes behind preventable medical errors, alerting clinicians to potentially significant contraindications and identifying safer courses of care. At Willis, we recognize the unique value of PeriGen's products and services in preventing errors and improving clinical outcomes, and we are proud to offer PeriGen's solutions to our clients."

PeriGen's integrated fetal monitoring, documentation, and clinical decision support systems help over 15,000 clinicians provide safer care to their patients. Additionally, PeriGen helps hospitals to improve clinical and financial outcomes through the design and implementation of risk management and patient safety initiatives, clinical quality improvement programs, perinatal training courses, business improvement programs, and revenue enhancement strategies. PeriGen's solutions are complemented by a full suite of patented, proprietary technologies, which represent the next generation of clinical decision support tools for Obstetrics. Providing real-time, interactive guidance at the patient's bedside, PeriGen's fetal monitor and OB patient record facilitate the delivery of consistent, repeatable high-quality care.

"It is common for insurance brokers to anticipate risk, but Willis is unique in its approach to claims prevention," said Donald A. Deieso, Ph.D., Chairman and CEO of PeriGen. "Recognizing that the most effective guard against medical malpractice claims is high-quality, evidence-based care, Willis has chosen to arm its clients with PeriGen's sophisticated risk management and quality improvement tools. We are proud to collaborate with an insurance broker of Willis' caliber and foresight, and we are honored to have been selected to share our offerings with Willis' client base."

About PeriGen, Inc. PeriGen is a technology-enabled professional services company specializing in risk reduction and clinical quality improvement in Obstetrics and is the only OB-specific risk reduction company to provide solutions which generate immediate, quantifiable and clinical value. Singularly focused on reducing risk and improving financial performance, PeriGen's advanced clinical decision support and fetal monitoring solutions are installed in over 100 hospitals across North America. A pioneer in advanced clinical decision support, PeriGen provides innovative solutions and a full suite of complementary professional and consulting services that reduce risk and improve clinical outcomes. PeriGen is a US corporation headquartered in Princeton, New Jersey, with offices in Canada and Israel. For more information, please visit us at

About WillisWillis Group Holdings plc is a leading global insurance broker, developing and delivering professional insurance, reinsurance, risk management, financial and human resource consulting and actuarial services to corporations, public entities and institutions around the world. Willis has more than 400 offices in nearly 120 countries, with a global team of approximately 17,000 employees serving clients in virtually every part of the world. Additional information on Willis may be found at Sandra Taylor, Ph.D.Chief Marketing Officer, PeriGen (609) Colleen McCarthyDirector of Communications, Willis(212) 915-8307

SOURCE PeriGen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Allegheny General Hospital Performs First Liver Transplant
2. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
3. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
4. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
7. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
8. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
9. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. Huntington Hospital Surgeon Performs First Single Port Resection on Colorectal Cancer Patient in CA
Post Your Comments:
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):